thisdrug what a medicine's name tells you

WHO naming stem · suffix · 31 listed names

-(ar)abine

This page was written with AI.

arabinofuranosyl derivatives

WHO's definition, quoted as written in the 2024 stem book

10 of 31 names appear in these lists: 10 in the US list (FDA Drugs@FDA) and 6 in the EU central list (EMA); 8 have national brands in at least one EU/EEA country.

Names only. This page is about -(ar)abine as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -(ar)abine. It has 2 spellings or places: arabine at the end of the name (…arabine); abine at the end of the name (…abine).

Of the 31 names WHO lists under it, 7 carry arabine at the end of the name, 24 carry abine at the end of the name.

All 31 names WHO lists under -(ar)abine

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 10 of 31 names appear in these lists: 10 in the US list (FDA Drugs@FDA) and 6 in the EU central list (EMA); 8 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. ancitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  2. apricitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. aspacytarabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  4. capecitabine
    US brands: XELODA (discontinued in FDA listings)
  5. clofarabine
    US brands: CLOLAR (discontinued in FDA listings)
    EU (central) brands: Evoltra, Ivozall (withdrawn)
  6. cytarabine
    US brands: CYTOSAR-U (discontinued in FDA listings), DEPOCYT (discontinued in FDA listings)
    in combination: VYXEOS with daunorubicin
    EU (central) brands: DepoCyte (withdrawn)
    in combination: Vyxeos liposomal with daunorubicin
  7. decitabine
    US brands: DACOGEN (discontinued in FDA listings)
    in combination: INQOVI with cedazuridine
    EU (central) brands: Dacogen
    in combination: Inaqovi with cedazuridine
  8. dexelvucitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. elvucitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  10. emtricitabine
    US brands: EMTRIVA
    in combination: BIKTARVY with bictegravir + tenofovir alafenamide; COMPLERA with rilpivirine + tenofovir disoproxil; DESCOVY with tenofovir alafenamide; GENVOYA with cobicistat + elvitegravir + tenofovir alafenamide; ODEFSEY with rilpivirine + tenofovir alafenamide; STRIBILD with cobicistat + elvitegravir + tenofovir disoproxil; SYMTUZA with cobicistat + darunavir + tenofovir alafenamide; TRUVADA with tenofovir disoproxil; ATRIPLA (discontinued in FDA listings) with efavirenz + tenofovir disoproxil
    EU (central) brands: Emtriva
    in combination: Biktarvy with bictegravir + tenofovir alafenamide; Descovy with tenofovir alafenamide; Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with efavirenz + tenofovir disoproxil; Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan with efavirenz + tenofovir disoproxil; Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva with efavirenz + tenofovir disoproxil; Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris with rilpivirine + tenofovir alafenamide; Emtricitabine / Tenofovir alafenamide Viatris with tenofovir alafenamide; Emtricitabine/Tenofovir disoproxil Krka with tenofovir disoproxil; Emtricitabine/Tenofovir disoproxil Krka d.d. with tenofovir disoproxil; Emtricitabine/Tenofovir disoproxil Mylan with tenofovir disoproxil; Emtricitabine/Tenofovir disoproxil Zentiva with tenofovir disoproxil; Eviplera with rilpivirine + tenofovir disoproxil
    6 moreGenvoya with cobicistat + elvitegravir + tenofovir alafenamide; Odefsey with rilpivirine + tenofovir alafenamide; Stribild with cobicistat + elvitegravir + tenofovir disoproxil; Symtuza with cobicistat + darunavir + tenofovir alafenamide; Truvada with tenofovir disoproxil; Atripla (withdrawn) with efavirenz + tenofovir disoproxil
  11. enocitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. fazarabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  13. fiacitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  14. fludarabine
    US brands: FLUDARA (discontinued in FDA listings), OFORTA (discontinued in FDA listings)
    EU (central) brands: none found
  15. flurocitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  16. fosgemcitabine palabenamide
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  17. galocitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  18. gemcitabine
    US brands: AVGEMSI, INLEXZO, GEMZAR (discontinued in FDA listings), INFUGEM (discontinued in FDA listings)
    EU (central) brands: none found
  19. guadecitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  20. ibacitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  21. lumicitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  22. mericitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  23. nelarabine
    US brands: ARRANON
    EU (central) brands: Atriance
  24. sapacitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  25. tezacitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  26. torcitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  27. troxacitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  28. valopicitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  29. valtorcitabine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  30. vidarabine
    US brands: VIRA-A (discontinued in FDA listings)
    EU (central) brands: none found
  31. zalcitabine
    US brands: HIVID (discontinued in FDA listings)
    EU (central) brands: none found

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Same group, without the stem

WHO also lists these 2 names under -(ar)abine: group (c) of Part IV of the 2024 stem book, “INN which belong to the same group of pharmaceutical substances but in which the stem is not used”. They belong to the same group of substances as the group (a) names above, yet they do not carry -(ar)abine, so the name alone does not reveal the group.

  1. ribavirin
  2. taribavirin

Decode another name

Decoded

cytarabine

Listed INNCarries 2 WHO stems, most specific first: -(ar)abine …

  • -(ar)abineend of the nameWHO lists it hereWHO definition: arabinofuranosyl derivatives
  • -abineend of the nameWHO lists it hereWHO definition: arabinofuranosyl derivatives; nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives

“cytarabine” is an INN that WHO lists under -(ar)abine, -abine in the 2024 stem book. WHO’s 2024 stem book lists “cytarabine” under -citabine as a name of the same group of substances in which the stem is not used (group c).

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -(ar)abine (Part II B) and the 31 names (Part IV, group (a)), and the 2 of the same group without the stem (group (c)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy